KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Globus Medical (GMED) EBIT Margin (2016 - 2025)

Globus Medical's EBIT Margin history spans 15 years, with the latest figure at 20.49% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 1132.0% year-over-year to 20.49%; the TTM value through Dec 2025 reached 16.33%, up 974.0%, while the annual FY2025 figure was 16.33%, 974.0% up from the prior year.
  • EBIT Margin reached 20.49% in Q4 2025 per GMED's latest filing, up from 17.86% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 25.71% in Q2 2022 to a low of 0.11% in Q3 2023.
  • Average EBIT Margin over 5 years is 14.87%, with a median of 18.07% recorded in 2021.
  • Peak YoY movement for EBIT Margin: soared 3544bps in 2021, then plummeted -2339bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 7.28% in 2021, then surged by 170bps to 19.68% in 2022, then plummeted by -92bps to 1.64% in 2023, then skyrocketed by 458bps to 9.17% in 2024, then soared by 123bps to 20.49% in 2025.
  • Per Business Quant, the three most recent readings for GMED's EBIT Margin are 20.49% (Q4 2025), 17.86% (Q3 2025), and 10.21% (Q2 2025).